Search Results - "Mao, Qunying"

Refine Results
  1. 1

    Risk management of project information system operation and maintenance based on Cloud Computing by Mao, Qunying

    “…In this experiment, according to the actual situation and content of the project information system operation and maintenance project, combined with the…”
    Get full text
    Journal Article
  2. 2
  3. 3
  4. 4

    COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations by He, Qian, Mao, Qunying, Zhang, Jialu, Bian, Lianlian, Gao, Fan, Wang, Junzhi, Xu, Miao, Liang, Zhenglun

    Published in Frontiers in immunology (12-04-2021)
    “…The world has entered the second wave of the COVID-19 pandemic, and its intensity is significantly higher than that of the first wave of early 2020. Many…”
    Get full text
    Journal Article
  5. 5

    Heterologous prime-boost: breaking the protective immune response bottleneck of COVID-19 vaccine candidates by He, Qian, Mao, Qunying, An, Chaoqiang, Zhang, Jialu, Gao, Fan, Bian, Lianlian, Li, Changgui, Liang, Zhenglun, Xu, Miao, Wang, Junzhi

    Published in Emerging microbes & infections (2021)
    “…COVID-19 vaccines emerging from different platforms differ in efficacy, duration of protection, and side effects. To maximize the benefits of vaccination, we…”
    Get full text
    Journal Article
  6. 6

    Research progress on circular RNA vaccines by Bai, Yu, Liu, Dong, He, Qian, Liu, Jianyang, Mao, Qunying, Liang, Zhenglun

    Published in Frontiers in immunology (12-01-2023)
    “…Owing to the success of linear mRNA coronavirus disease 2019 (COVID-19) vaccines, biopharmaceutical companies and research teams worldwide have attempted to…”
    Get full text
    Journal Article
  7. 7

    Research Advances on the Stability of mRNA Vaccines by Cheng, Feiran, Wang, Yiping, Bai, Yu, Liang, Zhenglun, Mao, Qunying, Liu, Dong, Wu, Xing, Xu, Miao

    Published in Viruses (01-03-2023)
    “…Compared to other vaccines, the inherent properties of messenger RNA (mRNA) vaccines and their interaction with lipid nanoparticles make them considerably…”
    Get full text
    Journal Article
  8. 8

    Research progress on substitution of in vivo method(s) by in vitro method(s) for human vaccine potency assays by Zhang, Xuanxuan, Wu, Xing, He, Qian, Wang, Junzhi, Mao, Qunying, Liang, Zhenglun, Xu, Miao

    Published in Expert review of vaccines (31-12-2023)
    “…Potency is a critical quality attribute for controlling quality consistency and relevant biological properties of vaccines. Owing to the high demand for…”
    Get full text
    Journal Article
  9. 9

    A Neonatal Mouse Model of Coxsackievirus A16 for Vaccine Evaluation by Mao, Qunying, Wang, Yiping, Gao, Rong, Shao, Jie, Yao, Xin, Lang, Shuhui, Wang, Chao, Mao, Panyong, Liang, Zhenglun, Wang, Junzhi

    Published in Journal of Virology (01-11-2012)
    “…OA  Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+…”
    Get full text
    Journal Article
  10. 10

    Research progress on the quality control of mRNA vaccines by Hu, Chaoying, Bai, Yu, Liu, Jianyang, Wang, Yiping, He, Qian, Zhang, Xuanxuan, Cheng, Feiran, Xu, Miao, Mao, Qunying, Liang, Zhenglun

    Published in Expert review of vaccines (31-12-2024)
    “…The mRNA vaccine technologies have progressed rapidly in recent years. The COVID-19 pandemic has accelerated the application of mRNA vaccines, with research…”
    Get full text
    Journal Article
  11. 11

    EV-A71 vaccine licensure: a first step for multivalent enterovirus vaccine to control HFMD and other severe diseases by Mao, Qunying, Wang, Yiping, Bian, Lianlian, Xu, Miao, Liang, Zhenglun

    Published in Emerging microbes & infections (2016)
    “…Enteroviruses (EVs) are the most common viral agents in humans. Although most infections are mild or asymptomatic, there is a wide spectrum of clinical…”
    Get full text
    Journal Article
  12. 12

    Amplifying mRNA vaccines: potential versatile magicians for oncotherapy by Hu, Chaoying, Liu, Jianyang, Cheng, Feiran, Bai, Yu, Mao, Qunying, Xu, Miao, Liang, Zhenglun

    Published in Frontiers in immunology (23-10-2023)
    “…Cancer vaccines drive the activation and proliferation of tumor-reactive immune cells, thereby eliciting tumor-specific immunity that kills tumor cells…”
    Get full text
    Journal Article
  13. 13

    Boosting with heterologous vaccines effectively improves protective immune responses of the inactivated SARS-CoV-2 vaccine by Zhang, Jialu, He, Qian, An, Chaoqiang, Mao, Qunying, Gao, Fan, Bian, Lianlian, Wu, Xing, Wang, Qian, Liu, Pei, Song, Lifang, Huo, Yaqian, Liu, Siyuan, Yan, Xujia, Yang, Jinghuan, Cui, Bopei, Li, Changgui, Wang, Junzhi, Liang, Zhenglun, Xu, Miao

    Published in Emerging microbes & infections (01-01-2021)
    “…Since the outbreak of COVID-19, a variety of vaccine platforms have been developed. Amongst these, inactivated vaccines have been authorized for emergency use…”
    Get full text
    Journal Article
  14. 14

    A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model by Zhang, Yi, Zhang, Jialu, Li, Dongmei, Mao, Qunying, Li, Xiuling, Liang, Zhenglun, He, Qian

    Published in Viruses (01-03-2024)
    “…Severe acute respiratory syndrome (SARS)-coronavirus (CoV), Middle Eastern respiratory syndrome (MERS)-CoV, and SARS-CoV-2 have seriously threatened human life…”
    Get full text
    Journal Article
  15. 15

    Establishment of the 1st Chinese national standard for CA6 neutralizing antibody by Wang, Yiping, Gao, Fan, Liang, Zhenglun, Sun, Huimin, Wang, Junzhi, Mao, Qunying

    Published in Human vaccines & immunotherapeutics (31-12-2023)
    “…Coxsackievirus A6 (CA6) is one of the major causative agents of herpangina and hand-foot-mouth disease (HFMD). Since 2008, CA6 has circulated widely around the…”
    Get full text
    Journal Article
  16. 16
  17. 17

    COVID-19 vaccines: progress and understanding on quality control and evaluation by Mao, Qunying, Xu, Miao, He, Qian, Li, Changgui, Meng, Shufang, Wang, Yiping, Cui, Bopei, Liang, Zhenglun, Wang, Junzhi

    Published in Signal transduction and targeted therapy (18-05-2021)
    “…The outbreak of COVID-19 has posed a huge threat to global health and economy. Countermeasures have revolutionized norms for working, socializing, learning,…”
    Get full text
    Journal Article
  18. 18

    Research progress on vaccine efficacy against SARS-CoV-2 variants of concern by Bian, Lianlian, Liu, Jianyang, Gao, Fan, Gao, Qiushuang, He, Qian, Mao, Qunying, Wu, Xing, Xu, Miao, Liang, Zhenglun

    Published in Human vaccines & immunotherapeutics (30-11-2022)
    “…Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to circulate worldwide and a variety of variants have emerged. Variants of concern (VOC)…”
    Get full text
    Journal Article
  19. 19

    Considerations for the Feasibility of Neutralizing Antibodies as a Surrogate Endpoint for COVID-19 Vaccines by Liu, Jianyang, Mao, Qunying, Wu, Xing, He, Qian, Bian, Lianlian, Bai, Yu, Wang, Zhongfang, Wang, Qian, Zhang, Jialu, Liang, Zhenglun, Xu, Miao

    Published in Frontiers in immunology (27-04-2022)
    “…To effectively control and prevent the pandemic of coronavirus disease 2019 (COVID-19), suitable vaccines have been researched and developed rapidly…”
    Get full text
    Journal Article
  20. 20

    Progress and challenges in the clinical evaluation of immune responses to respiratory mucosal vaccines by Zhang, Xuanxuan, Zhang, Jialu, Chen, Si, He, Qian, Bai, Yu, Liu, Jianyang, Wang, Zhongfang, Liang, Zhenglun, Chen, Ling, Mao, Qunying, Xu, Miao

    Published in Expert review of vaccines (2024)
    “…Following the coronavirus disease pandemic, respiratory mucosal vaccines that elicit both mucosal and systemic immune responses have garnered increasing…”
    Get full text
    Journal Article